Introduction
Non-insulin dependent diabetes mellitus (NIDDM) is an increasingly common and important cause of morbidity and mortality throughout the world. Hyperglycaemia in NIDDM is due to variable combinations of a relative decrease in insulin secretion and by insulin insensitivity in peripheral tissues, notably the liver and skeletal muscle (DeFronzo, 1988) . NIDDM and the pre-diabetic state of impaired glucose tolerance (IGT) have been estimated to aect at least 3 ± 5% of the population world-wide, and 10 ± 20% of subjects over 60 years of age (Harris, 1996) . Current treatment of NIDDM patients hinges on attempts to correct insulin de®ciency with insulin secretagogues (especially sulphonylureas) or insulin itself. The biguanides, notably metformin, reduce hyperglycaemia and improve some aspects of the insulin insensitivity associated with NIDDM (Williams, 1994) .
The thiazolidinediones are a novel class of compounds that enhance insulin action and are currently under evaluation as antidiabetic drugs (Suter et al., 1992; Nolan et al., 1994; Kumar et al., 1996) . Their action is thought to be primarily on adipose tissue where they act as agonists at the peroxisome proliferator activator receptor-gamma subtype (PPAR-gamma) nuclear receptor (Lehmann et al., 1996; Wilson et al., 1996) . This alters the transcription of multiple genes leading to reduced lipolysis, increased triglyceride accumulation and decreased plasma non-esteri®ed free fatty acid concentrations (Forman et al., 1995) . The reduction in plasma non-esteri®ed fatty acid concentrations leads to increased glucose utilization in muscle (Randle et al., 1964) , reduced hepatic gluconeogenesis and improved suppression of hepatic glucose output by insulin (Bowen et al., 1991; Oakes et al., 1994) .
Several thiazolidinediones are undergoing clinical trials and have been shown to be bene®cial in both NIDDM (decreasing blood glucose and plasma insulin concentrations) and in impaired glucose tolerance (Suter et al., 1992; Nolan et al., 1994) suggesting that thiazolidinediones, such as troglitazone, may be useful in preventing NIDDM.
We have examined the eects of the thiazolidinedione, MCC-555 ((+)-5-[{6-(2-¯uorbenzyl)-oxy-2-naphy}methyl]-2,4-thiazolidinedione) on plasma insulin, glucose and nonesteri®ed fatty acid concentrations and insulin sensitivity of obese (fa/fa) Zucker rats and Zucker Diabetic Fatty (ZDF) rats. MCC-555 has been demonstrated to reduce the hyperglycaemia and hyperinsulinaemia in the diabetic KKA y mouse model to levels measured in non-diabetic mice, with a greater potency that either pioglitazone or troglitazone (Kadowaki, personal communication) and lacks haematological and cardiac side eects (Ishii et al., 1996) . Both obese Zucker rats and diabetic ZDF rats develop morbid obesity through the fa mutation in the extracellular domain of the leptin receptor, which interferes with leptin's centrallymediated appetite-suppressing and thermogenic actions, tending to severe insulin resistance (Clark & Palmer, 1982; Peterson, 1994; Sturgis et al., 1995; Sreenan et al., 1996) . Unlike the ZDF rats, which are fully diabetic, obese Zucker rats represent an important animal model for the study of impaired glucose tolerance (IGT) since they display a mild hyperglycaemia, pronounced hyperinsulinaemia and a marked reduction in insulin sensitivity (Terrettaz & Jeanrenaud, 1983) . ZDF rats, unlike obese Zucker rats, have a b-cell defect which progresses to a state of insulin de®ciency analogous to human NIDDM, characterized by marked hyperglycaemia and overt diabetic symptoms of polyuria and polydipsia and ultimately to weight loss (Peterson, 1994) .
The aims of the study were to determine whether MCC-555 can improve insulin sensitivity in both obese Zucker rats and diabetic ZDF rats and also attenuate the key metabolic disorders associated with the diabetic state in ZDF rats.
Methods

Animal procedures
Male lean (204 ± 236 g) and obese (341 ± 403 g) Zucker rats were obtained from Harlan Olac, Bicester, U.K. Ten week old male lean (276 ± 331 g; Gmi-fal + ) and diabetic (319 ± 372 g; fa/ fa) ZDF rats were purchased from Genetic Models Inc. (Indianapolis, IN, U.S.A). Animals were housed individually in wire-bottomed cages for a period of 1 week before treatment and maintained on a 12 h dark/light cycle (lights on 07.00) with free access to standard lab chow (CRM, Biosure, Cambridge, U.K.) and tap water. Groups of eight obese Zucker rats and eight diabetic ZDF rats were dosed with vehicle (0.5% sodium carboxymethylcellulose in water 5 ml/ kg ) by gavage for 21 days. Groups of eight lean Zucker or eight non-diabetic ZDF rats received vehicle alone for 21 days. Body weight, food and water consumption were recorded daily. Twenty-four hours after the last dose of vehicle or MCC-555, fed rats were killed using CO 2 inhalation and blood removed via cardiac puncture into cold heparinized tubes. After a brief centrifugation at 48C, plasma was frozen in aliquots for the later determination of glucose, non-esteri®ed fatty acid, triglyceride and insulin concentrations. Approximately 1 g of liver was dissected, snap-frozen in liquid nitrogen and stored at 7408C for later measurements of hepatic glycogen concentrations and glycogen synthase activity. The carcasses of a group of vehicle-treated lean and vehicle and MCC-555-treated obese Zucker rats were homogenized using a food processor and frozen for later estimations of the body lipid content.
All animal care, monitoring and procedures were carried out in accordance with strict guidelines issued by the U.K. Home Oce. 71 for 1 h. After 1 min, 5% glucose in isotonic saline was co-infused at an initial rate of 1 mg min 71 through the jugular vein. Blood glucose concentrations were measured every 5 min from the tail vein using an Exactech electrochemical meter (Medisense, Abingdon, Oxon, U.K.) and the glucose infusion rate adjusted to maintain stable blood glucose levels of 4.2 mmol l 71 in lean Zucker and non-diabetic ZDF rats, 5.2 mmol l 71 in obese Zucker rats and 20 mmol l 71 in diabetic ZDF rats. Glucose appearance and uptake were calculated from blood speci®c activity as described by Terrettaz & Jeanrenaud (1983) . Blood samples were collected at 0, 30 and 90 min of clamping into cold heparinized tubes, immediately centrifuged and kept on ice. Fifty microlitres of plasma were deproteinized with 25 ml 83 mM ZnSO 4 and 25 ml 87 mM Ba(OH) 2 , centrifuged (14,000 r.p.m.) for 1 min and 50 ml of the supernatant was evaporated to remove 3 H 2 O in order to determine blood glucose speci®c activity. Radioactivity was measured by scintillation spectrometry using 3 ml scintillation cocktail (Cocktail T. BDH, Poole, Dorset, U.K.) and an LKB counter (counting eciency=45%). Total unlabelled glucose appearance was calculated from plasma glucose concentrations and glucose speci®c activity in blood, taking into account the dierence in glucose space in lean and obese rats (Katz et al., 1974 ; glucose space=25% of body weight).
Euglycaemic hyperinsulinaemic clamp studies
Biochemical measurements
Plasma insulin concentrations were measured using a commercially available radioimmunoassay kit (Pharmacia/ Upjohn Diagnostics U.K., Lewes, East Sussex). Plasma glucose, non-esteri®ed fatty acid and triglyceride concentrations were measured using standard kits from Boehringer Mannheim (Milton Keynes, Bucks., U.K.) and Sigma Chemical Company, (Poole, Dorset, U.K.).
Whole-body fat mass was measured using a modi®ed method of Folch et al. (1956) . Brie¯y, the frozen homogenized carcass was weighed, freeze-dried and homogenized in a food processor. A small amount of the homogenized tissue (1.5 g) was added to a mixture of chloroform/methanol (2 : 1) and homogenized further using a polytron to dissolve the fat. The extract was ®ltered through fat-free Whatman ®lter paper and mixed with 0.05% (w/v) CaCl 2 (0.2 vols). When the mixture had separated into two phases, the upper phase was removed and the interphase washed three times with chloroform/methanol/CaCl 2 (2 : 1 : 0.02) taking care not to disturb the lower layer. The lower organic phase containing the dissolved lipids was placed in preweighed glass scintillation vials and the solvent evaporated o. The vials containing the remaining lipids were reweighed. The percentage body fat mass was calculated from the dry carcass mass.
Liver glycogen content was measured using the method of (Lowry, 1972) and hepatic glycogen synthase activity was measured using [ 14 C]-UDP-glucose (292 mCi mmol 71 , Amersham International plc, Little Chalfont, Bucks, U.K.) according to the method of Thomas et al. (1968) . Liver glycogen concentrations are expressed as mmol glucose incorporated into glycogen per g tissue wet weight, the glycogen synthase activity as mmol min 71 g wet weight
71
.
Improved metabolic status in Zucker and ZDF rats by MCC-555 1709 R. Upton et al
Statistical analyses
Dierences between MCC-555-treated rats and vehicle-treated rats were analysed using one-or two-way analysis of variance (ANOVA) followed by Bonferroni modi®ed t-tests for multiple comparisons.
Results
Zucker rats
As expected, vehicle-treated obese rats ate more than lean rats (Figure 1 ). Daily food consumption of MCC-555-treated obese Zucker rats did not dier signi®cantly from vehicle-treated obese rats at either dose throughout. However, the cumulative food consumption of obese rats treated with 30 mg kg 71 , but not with 10 mg kg 71 (not shown), MCC-555 was signi®cantly greater than vehicle-treated obese rats during the last 10 days of the study. Both groups of obese rats were demonstrated signi®cantly hyperphagic, as compared to vehicle-treated lean rats. There was no change in the daily water consumption of MCC-555-treated obese Zucker rats as compared to controls (Table 1) . Daily administration with 30 mg kg 71 MCC-555 did not signi®cantly alter the ®nal body weights of obese Zucker rats, as compared to vehicle-treated obese controls, but both groups of obese rats remained signi®cantly heavier than vehicle-treated lean animals (Table 1) and there was no eect on body weight following daily administration of 10 mg kg 71 MCC-555 (not shown). The percentage body fat was 4 fold larger in untreated obese Zucker rats than in lean rats, but was not signi®cantly modi®ed by MCC-555 treatment (Table 1) .
After 21 days of MCC-555 treatment, plasma triglyceride and non-esteri®ed fatty acid concentrations were signi®cantly reduced in obese Zucker rats receiving 30 mg kg 71 MCC-555, as compared with vehicle-treated rats, but plasma triglyceride concentrations were not reduced to levels observed in lean rats (Table 1 ). The modest hyperglycaemia of obese Zucker rats was partially normalized by 30 mg kg 71 MCC-555 (Table 1 ) and 10 mg kg 71 MCC-555 treatment but their hyperinsulinaemia was unchanged (Table 1) . Liver glycogen concentrations, but not glycogen synthase activity, were signi®cantly increased in MCC-555-treated rats (30 mg kg 71 ), as compared with both vehicle treated obese and lean rats (Table 1) .
Infusion of insulin to both lean and obese Zucker rats during euglycaemic hyperinsulinaemic clamping conditions elevated plasma insulin concentrations in all groups (Table 3) . During the last minute of the clamp, signi®cantly higher glucose infusion rates were required to maintain euglycaemia in vehicle treated lean and MCC-555-treated obese rats, as compared with vehicle-treated obese rats (Table 3) . Basal hepatic glucose production was similar in all three groups of Zucker rats (Figure 2 ), but hyperinsulinaemia during clamping completely inhibited hepatic glucose production in vehicletreated lean rats with no signi®cant change in vehicle-treated obese rats. However, chronic MCC-555 treatment failed to signi®cantly reduce hepatic glucose production in obese Figure 1 Cumulative food consumption in MCC-555-and vehicletreated obese Zucker rats and in lean Zucker rats. Also cumulative body weight in MCC-555-and vehicle-treated diabetic ZDF rats and vehicle-treated non-diabetic rats. Data shown as mean+s.e.mean for groups of eight rats/group. 
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Zucker rats under hyperinsulinaemic conditions. At baseline there was no signi®cant dierence in the whole-body glucose uptake between MCC-555-treated obese rats and vehicletreated lean and obese rats (Figure 2) . During clamping conditions, however, whole-body glucose uptake increased by 100% in vehicle-treated lean rats and by 58% in MCC-555-treated obese rats. In contrast, whole-body glucose uptake was increased by only 11% in vehicle-treated obese rats (Figure 2 ).
Diabetic ZDF rats
There was no signi®cant increase in body weight gain of vehicle-treated diabetic ZDF rats during the experimental period whereas vehicle-treated lean ZDF rats demonstrated a signi®cant increase in body weight ( Figure 1, Table 2 ). MCC-555-treated diabetic rats demonstrated a small increase in body weight over the experimental period that was signi®cantly dierent from vehicle-treated controls by day 21 (Figure 1 , Table 2 ). Daily and the cumulative food consumption of vehicle-and MCC-555-treated diabetic ZDF rats were not signi®cantly dierent from one another, but both groups ate signi®cantly more than non-diabetic, lean controls ( Table 2 ). The marked polydipsia of diabetic rats was not signi®cantly attenuated by MCC-555 treatment nor were there any signi®cant alterations in plasma glucose or triglyceride concentrations (Table 2 ). However, plasma insulin concentrations were signi®cantly reduced in MCC-555-treated diabetic ZDF rats prior to clamping (Table 3) and there was also a trend for lower insulin concentrations in another group of MCC-555-treated diabetic ZDF rats, as compared to vehicletreated diabetic ZDF rats (Table 2) .
Plasma non-esteri®ed fatty acid concentrations were, however, signi®cantly reduced in MCC-555-treated versus vehicle-treated diabetic ZDF rats (Table 2 ). There was a signi®cant increase in the gonadal and perirenal fat pad mass, liver glycogen content and hepatic glycogen synthase activity of MCC-555-treated diabetic rats as compared to vehicletreated diabetic and lean controls ( Table 2) .
Infusion of insulin to both diabetic and lean ZDF rats during clamping conditions elevated plasma insulin concentrations in all groups (Table 3) . Steady-state glucose infusion rates required to maintain euglycaemia were signi®cantly dierent between MCC-555-and vehicle-treated diabetic rats (Table 3) . However, glucose infusion rates for MCC-555-treated diabetic rats remained less than those required for non-diabetic vehicletreated controls (Table 3) .
Basal hepatic glucose production was signi®cantly greater in diabetic ZDF rats, with or without MCC-555 treatment, when compared with lean rats (Figure 3 ). During clamp conditions there was a signi®cant inhibition in hepatic glucose production in both vehicle-treated lean rats and diabetic rats treated with MCC-555 (Figure 3) . However, vehicle-treated diabetic rats did not exhibit signi®cant suppression of glucose production during clamping. Whole-body glucose uptake was signi®cantly increased in diabetic ZDF rats treated with MCC-555 as compared with vehicle-treated diabetic controls, but did not Figure 2 Hepatic glucose production and whole body glucose uptake in MCC-555-treated and vehicle-treated lean and obese Zucker rats under basal and hyperinsulinaemic conditions. Data shown as mean+s.e.mean for groups of eight rats. *P50.05, **P50.01 as compared to basal hepatic glucose output or whole body glucose uptake. Data shown as mean+s.e.mean for groups of eight to ten rats. *P50.05, **P50.01 as compared to vehicle-treated lean rats, {P50.05 as compared to vehicle-treated diabetic rats.
quite reach levels measured in vehicle-treated lean non-diabetic controls (Figure 3 ).
Discussion
Reduced sensitivity to various biological eects of insulin is a fundamental abnormality of noninsulin dependent diabetes mellitus (NIDDM) in animals and humans (Terrettaz & Jeanrenaud, 1983) and drugs that signi®cantly improve insulin sensitivity are likely to be potentially useful in the treatment of the disease. Here, we examined the eects of chronic MCC-555 treatment on the metabolic status of obese Zucker rats, which display morbid obesity associated with insulin insensitivity and impaired glucose tolerance and on ZDF rats which are overtly diabetic. Chronic treatment of obese Zucker and diabetic ZDF rats with MCC-555 signi®cantly increased insulin sensitivity, as determined by the increase in glucose infusion rates to maintain euglycaemia under hyperinsulinaemic conditions. The signi®cant reduction in plasma non-esteri®ed fatty acid concentrations following MCC-555-treatment to both obese Zucker and diabetic ZDF rats is consistent with studies of other thiazolidinediones, such as troglitazone and BRL 49653 (rosiglitazone) (Oakes et al., 1994; Sreenan et al., 1996) and suggests that MCC-555 acts as a potent PPAR-gamma agonist thereby increasing gene expression coding for enzymes that regulate lipolysis in adipose tissue (Lehmann et al., 1995) . The reduction in non-esteri®ed fatty acid concentrations have been suggested to play a key role in improving insulin sensitivity in skeletal muscle and adipose tissue via alterations in metabolism acting through the glucose-fatty acid cycle (Randle et al., 1964; Oakes et al., 1994) . However, we cannot exclude the possibility that MCC-555 may improve insulin sensitivity through the blockade of protein kinase C translocation from the cytoplasmic to particulate fractions, which has been demonstrated with other thiazolidinediones such as BRL 49653 (Schmitz-Peier et al., 1997) and troglitazone (BaÈ hr et al., 1996) and has been suggested to participate in improved insulin-sensitive glucose transport (Schmitz-Peier et al., 1997) .
The consequence of MCC-555-induced reductions in plasma non-esteri®ed fatty acid concentrations, and the improvement in insulin sensitivity was to reduce hepatic glucose production and increase glucose uptake into peripheral tissues. An increase in glucose entry into insulin-sensitive tissues was also observed by the signi®cant increase in hepatic glycogen concentrations in both Zucker and ZDF rats under hyperinsulinaemic conditions and increased fat pad mass in diabetic ZDF rats. The ®nding that glycogen concentrations in MCC-555-treated obese Zucker and diabetic ZDF rats were signi®cantly greater than those of lean Zucker or non-diabetic rats suggests that the thiazolidinedione signi®cantly increased the sensitivity of hepatic insulin-responsive elements above those of lean or non-diabetic animals resulting in enhanced glucose entry into the liver. Furthermore, the attenuation in hepatic glucose production following infusion of the insulin in Data shown as mean+s.e.mean for groups of eight rats. **P50.01 versus lean rats, {P50.05 versus vehicle-treated obese rats. Figure 3 Hepatic glucose production and the whole body glucose uptake of vehicle-treated non-diabetic and diabetic ZDF rats and diabetic ZDF rats treated with MCC-555 under basal and euglycaemic hyperinsulinaemic conditions. Data shown as mean+ s.e.mean for groups of seven to ten rats. *P50.05, **P50.01 as compared to basal hepatic glucose output or whole body glucose. {{P50.01 versus non-diabetic ZDF rats.
MCC-555-treated rats, as compared to vehicle-treated nondiabetic controls, is further evidence for increased insulin sensitivity in diabetic ZDF rats.
The improvements to insulin sensitivity resulted in an improved metabolic status in both obese Zucker and diabetic ZDF rats demonstrated by the modest increase in body weight gain in MCC-555-treated ZDF diabetic rats, without aecting food consumption. Despite the marked hyperphagia in diabetic ZDF rats, they do not continue to gain weight after 15 ± 20 weeks of age due to heavy losses of energy as glycosuria and catabolism resulting in lean ZDF rats exceeding them in bodyweight. Hyperglycaemia is typical of mature ZDF rats as a result of plasma insulin reductions from high values observed in young ZDF rats to those observed in young and older lean rats (Peterson 1994) . This indicates that insulin de®ciency has become the critical factor in causing metabolic decompensation, and that the syndrome has progressed beyond the phase where insulin insensitivity is the limiting factor and where improvements in insulin action would be most bene®cial. The body weight gain in diabetic ZDF rats following MCC-555 treatment is probably the result of increased glucose entry into adipose tissue and the conversion to triglycerides leading to increased fat mass. Increased body weight gain has been observed following 10 days of pioglitazone treatment to diabetic ZDF rats, but as there was no increase in fat deposition, the increased weight was attributed to water retention (deSouza et al., 1995) . The physiological mechanism resulting in the slight increase in food intake during MCC-555 treatment to obese Zucker rats is currently unknown, but has been also observed with other thiazolidinediones, such as BRL 49653 (rosiglitazone) (Eldershaw et al., 1995; Wang et al., 1997) , suggesting that this phenomenon is a general property of these compounds.
We could not ®nd evidence for changes in plasma glucose concentrations in MCC-555-treated diabetic ZDF rats although there was a small, but signi®cant reduction in plasma glucose concentration in obese Zucker rats. Some thiazolidinediones have previously been reported to reduce plasma glucose and insulin concentrations in the diabetic ZDF rat and obese Zucker rat (Sturgis et al., 1995; deSouza et al., 1995; Sreenan et al., 1996) but the eect may depend on age and severity of hyperglycaemia and the dose of thiazolidinedione used in the study, possible insulin secretagogue actions or eects on insulin clearance. Recently Smith et al. (1997) have also failed to observe a change in plasma insulin or glucose following treatment to diabetic ZDF rats with the potent thiazolidinedione, BRL 49653 (rosiglitazone), in older rats where the diabetic syndrome has been fully established. As we used older ZDF diabetic rats, which were 18 weeks of age at the end of the study by which the b-cell de®ciency, hyperglycaemia and relative insulin de®ciency had been fully established, it is probably dicult to improve b-cell function at this late stage in the development of the model. Sturgis and coworkers (1995) demonstrated that pioglitazone administered to 7-week old pre-diabetic ZDF rats prevented the hyperglycaemia that usually develops at 8 ± 10 weeks of age. However, pioglitazone administration at 11 weeks of age had no eect on plasma glucose or insulin concentrations in either obese Zucker or diabetic ZDF rats (Sturgis et al., 1995; Hirshman et al., 1995) supporting the contention that age and severity of diabetic symptoms determine the eects of thiazolidinediones on plasma insulin and glucose concentrations. Possibly other factors, such as thiazolidinedione-induced changes in insulin clearance and/or insulin secretagogue actions (Masuda et al., 1995) may account for the lack of change in plasma insulin concentrations in MCC-555-treated obese Zucker rats despite increased insulin sensitivity.
In conclusion, we have demonstrated that chronic treatment of obese Zucker and diabetic ZDF rats with the thiazolidinedione, MCC-555, signi®cantly improves insulin sensitivity and metabolic status of these rats. The overall eects of MCC-555 in overtly diabetic ZDF rats was to partially reverse the catabolic metabolic consequences of the diabetic state. In view of this improved responsiveness to insulin, MCC-555 may prove a promising candidate for the treatment of NIDDM.
